Disease Detail

ID DOID:4007
Name bladder carcinoma
Definition A urinary bladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR3 wild-type R3Mab bladder carcinoma sensitive detail...
FGFR3 S249C R3Mab bladder carcinoma sensitive detail...
AKT1 E17K NRAS Q61R BAY1125976 bladder carcinoma sensitive detail...
Unknown unknown AR-42 + Cisplatin bladder carcinoma not applicable detail...
HRAS Q61L NS1 bladder carcinoma sensitive detail...
MET wild-type Glesatinib bladder carcinoma decreased response detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00942331 Phase III Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting
NCT01259063 Phase Ib/II Everolimus + Gemcitabine RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder Completed
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Suspended
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Active, not recruiting
NCT01438112 Gemcitabine + interferon gamma + Mitomycin C + Valrubicin CG0070 Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Terminated
NCT01688999 Phase II Cabozantinib Cabozantinib for Advanced Urothelial Cancer Active, not recruiting
NCT01938573 Phase Ib/II Cisplatin + Gemcitabine + Sirolimus Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Completed
NCT02169284 Phase II Erlotinib Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery Terminated
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Recruiting
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT03171025 Phase II Nivolumab Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT) Recruiting
NCT03319745 Phase II Pembrolizumab A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy Recruiting
NCT03430895 Phase II Durvalumab + Tremelimumab Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Recruiting
NCT03693014 Phase II A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors Recruiting